



# CS MEDICA



#### **WE ARE**

A pioneer in cannabis OTC products, with a vision is to become a leading company in the cannabis medical treatment industry.

#### **WE CREATE**

With a scientific approach based on biochemistry and decades of experience within the global medical industry, we use modern technology to separate and research different compounds found in the cannabis plant to prevent and fight autoimmune diseases in effective and safe ways.

#### **WE BELIEVE**

We can help change millions of people with autoimmune and stress-related diseases with an easier every day and improved life quality with our products.

#### **WE AIM**

To be the **most trusted company and partner within the cannabinoid segment** – by delivering the products and concepts, with high efficacy, and no side effects, to people across the globe with autoimmune & stress-related illnesses.







#### THE MEDTECH DEFINITION

#### PART OF THE PHARMACEUTICAL INDUSTRY

The medical technology industry—often referred to as MedTech—comprises companies that Research & Develop, Manufacture, and Distribute the technologies, devices, equipment, diagnostic tests, and health information systems that are transforming health care through earlier disease detection, less-invasive procedures, and more effective treatments. MedTech is part of the pharmaceutical industry.

Life-changing CBD medical technologies allow millions of people to live longer, healthier, and more productive lives. The research and innovation to develop these cutting-edge CBD technologies allow CS Medica to continue leading in CBD medical advancements. From autoimmune to stress therapies, CS Medica changes healthcare for the benefit of patients and healthcare providers.

Our purpose is to create technologies & products that help improve the quality of life & reduce time spent in hospitals or in discomfort.



London Nov 2022





### **MEDTECH + GROWTH PHASES**

	STAGE	STAGE II	STAGE III	STAGE IV	STAGE V		
	RESEARCH	INTERMEDIATE PHASE		INDUSTRIALIZATION			
STAGE- GATED MODEL	BASIC RESERACH	INVENTION	EARLY DEVELOPMENT	PRODUCT DEVELOPMENT	MARKET APPROVAL & LAUNCH		
	INITIATION FORMULATION		CONCEPT TO PROTOTYPE; PRE-CLINICAL	PROTOTYPE: CLINICAL TO PRODUCT: PRE- APPROVAL	PRODUCT LAUNCH		
STARTUP	OPPORTUNITY	CONCEPT	DESIGN DEVELOPMENT	VERIFICATION	POST-MARKET ASSESMENT		
	CLINICAL NEED	FEASIBILITY	DEVELOPMENT OF PRODUCT, INCL REGULATION & PRODUCT- SPECIFIC STRATEGIES	VALIDATION	PAYING CUSTOMERS		
	FRAMEWORK CONDITIONS	BUSINESS DEVELOPMENT	MEDICAL ADVISORY BOARD OR CONSULTANTS				
	OWN CAPITAL/ STARTUP CAPITAL	IDENTIFY MEDTE	CH VENTURE CAPITAL	FINANCING OF ALL DEVELOPMENT & APPROVAL STAGES	FINANCING BOOST OF G2MARKET & MARKETING		
ACCESS TO DEVICE REGULATORY INFORMATION & CLINICAL EXPERTISE SUPPORT THROUGHOUT							

As a MedTech we are working at Stages III, IV & V (with 21 products in scope, 9 launched):


- New Product Development and Technologies
- Product Developing, verifying, and validating, securing patents
- Optimizing processes and trials, moving from MDD to MDR
- Launched finished products for brand build, post-market assessment, and revenue stream



### **OUR JOURNEY**

CANNASEN®
SCIENCE IS IN OUR NATURE

To become a leading provider of life-changing treatments for patients living with autoimmune, stress-related diseases and pain.






### **MARKET POTENTIAL**



# Covering the needs of pain, stress, and autoimmune disease management.

- Based on the unique therapeutic properties of cannabinoids from the cannabis plant.
- A diversified portfolio of wide market coverage.
- Increasing demand for solutions to stress and immune system-related conditions.
- Answers the need for pain management, especially for the aging population.







### **OUR CANNABINOID TECHNOLOGY**



# **Unique Findings & Study Patent Pending**

- CBD Isolate Pilot Study
- Discovery in the Natural Cannabinoid CBD's activity in the body
- **Unique technology** as the foundation for formulas
- High Bioavailability





#### TOPICAL/ TRANSDERMAL CBD

BIOAVAILABILITY 45%

Does not not enter the bloodstream.
The bioavailability is nigher as the liver's first so so effect is avoided, therefore there is no medicinal interaction.

#### NASAI CBD

BIOAVAILABILITY -34-46%

Enters the bloodstream.
The bioavailability is higher as the liver's fir pass effect is avoided therefore there is no medicinal interaction

#### ORA

BIOAVAILABILITY ~

Enters the bloodstream.
The bioavailability is lower due to the first pass effect in the live therefore there is medicinal interaction



### **BEING THE FIRST-MOVER**




#### **Medical Device products**

Currently the only company working with OTC Cannabis products under the pharmaceutical legislation.

- Solutions matching market needs for autoimmune and stress-related disorders, incl. animal treatment
- Clinically proven effective CBD products without any adverse events
- No known side effects
- Above 90% natural ingredients
- Few ingredients in formulas

Health, Pharma & Medtech > Pharmaceutical Products & Market

#### Leading reasons why U.S. adults use cannabidiol as of 2020





### THE LAUNCHED PORTFOLIO





#### Respiratory disorders We offer new treatments

for respiratory disorders like Allergy and insomnia, without any fatal side effects. We improve the lives of people's living with allergy. Allergy which is considered a pandemic among young people.



#### **Dermaceuticals**

We offer new innovative treatments for hair and skin, without any fatal side effects. We improve people's lives, who are losing their hair and have tendency of rosacea.










#### PROOF OF CONCEPT

# The Clinical Trials & Pre-Clinical studies for medical devices Registration ahead of competition

- Pre-clinical trials final.
- Post-clinical trials are partly final
- Registered as one of the only OTC Medical Devices under MDD transferring to MDR 2024 according to plan











### THE PIPELINE OF NPDs



With a unique CBD technology, we can reach several new segments in our mission to deliver safe, effective, and more natural alternative solutions to patients worldwide.

- New trials and tests
- Co-creation with partners

Product Registration	Desease indications	II	III IV
Medical device	Hotspot Gel - Dogs		Q3 2023
Veterinary	Muck Gel - Horses		Q3 2023
	Pain Patch - Horses		Q3 2023
	Pain Gel – Dogs & Horses		Q3 2023
Medical Device	Eyelash Enhancer		Q2 2024
Food for special	Arthritis		Q2 2023
medical	Psoriasis		Q3 2023
purpose/food sup.	Hair regrowth		Q3 2023
	Skincare line		Q2 2023
Cosmetic	Anti-Hair loss Shampoo		Q2 2023
	Anti-Hair loss Mask		Q2 2023
	Psoriasis Shampoo		Q4 2023
	Inhalator — сво		
Medicine	Inhalator — CBD + THC		
	Inhalator — CBD + Other Cannabinoid		

I: Formulation - II: Final Formulation - III: Lab. tests, invitro, invivo test & clinical studies - IV: Market launch



### **BUSINESS PLAN 2023**



2023									
	Q1	Q2	Q3	Q4					
NPDS	WOUND GEL COVID LOZENGES  ANTI HAIR LOSS HAIRCARE	VET	INHALER TREATMENT LINE SKIN CARE LINE						
TRIALS	PSOR VS PLACEBO  FOR PSOR HAIRCARE  CIM UPDATE/ GREENLIGHT	PUBLISH MIN 2 TRIALS ON SCIENCE PLATFORMS	SKIN CARE LINE						
PATENTS	DK PATENT TO PCT LANDING								
MARKETS	REST OF EU  THE UK  EMEA  PARTNER ID FOR US	US MARKET INCL AMAZON CHINA & INDIA AUSTRALIA & NZ SOUTH KOREA JAPAN CANADA	BRAZIL MEXICO SOUTH AFRICA						
CHANNELS	AMAZON FR, IT, UK, ES								
PRODUCT MRK	NEW PACKAGING NEW IFUS								
BRAND MRK	BRAND AWARENESS & TRAFFIC REFRAMED EQUITY STORY & COMMUNICATION STRATEGY	BRAND PLAYBOOKS	AWARENESS & SOCIAL COMMERCE						
FUNDING	NEW FUNDING	MAIN MARKET							



### **BUSINESS MODEL**




KEY PARTNERS  Suppliers Manufacturers Logistics Distributors & wholesalers Tech partners Freelancers & agencies Investors  KEY ACTIVITIES  Acquisition build Optimizing and expanding our market reach Grow brand awareness Drive trials results to market Ensure legislation Grow consumer pool by stimulating consumption Educate		VALUE PROPOSITION  POSITIONING: To bring change and relief to every patient with autoimmune and stress-related disorders with the therapeutic values of cannabinoids.  DtC: Relief and smoother everydays Natural, cleaner solutions THE alternative Community feel	CUSTOMER RELATIONSHIPS  - Guided Sales - Reviews & Influencers - Affiliates - Ecommerce - Partnerships - Social Commerce & Ecommerce with Education - Marketing Campaigns	CUSTOMER SEGMENTS  MACRO: CONDITIONS: Autoimmune, Pain, Arthritis, Sports Injuries, Psoriasis, Dry Skin, Hair Loss, Stress, Sleep & Breathing Challenged  GEO-DEMOGRAPHIC: Age, Gender, Urban Vs Rural, Lifestyle, Occupation, Etc
KEY RESOURCES  Good Culture & Values Skilled Passionate People R&D And Legislation Patents Brand Customer Base Retail Network Fulfilment Network	Value Delivery IT Assets (Subscription, PIM, CIM)     Disease Database     Influencers     Partners	BtB:  First-mover Advantage  Most Trusted Partner  CBD Benefits in OTC Products  Unique Range For Autoimmune Diseases, Stress & Pain+  Marketing Services  Own Brands  Investors:  Act on ESG	CHANNELS  • Ecommerce • Amazon • Pharmacies & stores • Professionals & Affiliates • Social Commerce • Marketing channels • Distributors & Wholesalers • White/Private Labels	BEHAVIORAL: Level Of Loyalty, Offers Used, Benefits Delivered, Frequency, Recommendations Etc)  PREFERED FUTURE  → MICRO: Personalized offers & Community  → Digital Audience defined based on data
COST STRUCTURE  Cost Of Goods: % Costs Of Sale: % Marketing: %. I GB: % R&D: % Technology & Content: % Fulfillment: %		PRICE MODEL  DtC Pricing Subscription Pricing Distribution Pricing Wholesale Pricing White/ Private Label Pricing	REVENUE STREAMS  DtC Ecommerce: € Subscription: € Amazon: € Online Stores: € Pharmacies: € Other: €	Physical Stores: € Distributors: € Wholesalers: € Marketing Services: € White/Private labels: € Third-Party brands: €



### **PRODUCT STRATEGY**



# Growing Market Awareness as First Movers while Volume helps fund further Brand Investment





### **PRODUCT COMPETITIVE MAPPING - EX**










BRAND NAME	VISUAL	PRICE	CBD	тнс	MEDICAL DEVICE	FOR SALE IN PHARMACIES	TEST AND TRIALS FOR SAFETY AND EFFICACY
DR KEERKLAN PAIN RELIEF	COLORON, MARINES MARINES AND COLORON COLORON	70 USD/ 60ML/ 180MG CBD	Full spectrum-Not purified, with traces of THC and other cannabinoids	Traces	NO	NO	ND
CANNARAY CBD MUSCLE BALM	CANNARAY  BE STANDARD OF STANDARD STAND	56USD/ 60ml/ 250MG CBD	Isolate	Traces	NO	NO	ND
CIBDOL CBD HEATING BALM	Control of	13USD/ 26g/ 52MG CBD	Isolate	NO	NO	NO	ND
CBD LONG TERM ACTION RECOVERY CREAM	920 920 930 930 930 930 930 930 930 930 930 93	45 USD/ 30ML/ 200MG CBD	Isolate	NO	NO	NO	ND
CBD Quick Action Recovery Gel	000 200 200 200 200 200	36 USD/ 30ML/ 200 MG CBD	Isolate	NO	NO	NO	ND
CANNASEN CBD Arthritis Gel	Archelia &	43 USD/ 50ML/ 500 mg	Isolate	NO	Yes	Yes	Yes



### **G2M STRATEGY**



#### **Dual Distribution with marketing support or at fee**







### **MARKETING STRATEGY**

You can't use an old map to explore a new world. Albert Einstein

Business Objectives	Marketing Priorities	Marketing Goals	Marketing Strategy	Key Actions	Dependencies and Risks			
Grow double- digit Growth	Brand Awareness Relevance	Increase reach & acquisition	Personalized Self- Care Community	Aggressive Acquisition	Production & Fulfillment			
CAGR 100 new	Traffic & CR	Grow frequency	Brand Activism & Cross-Generation Lead generation	Content-driven	Legislation			
partners and 5M customers by 2025	Social Influence Build & Education	& <b>CLV</b> Build partnerships with <b>data</b>		Social presence Data-driven	Spend /Funding Channel Mess			
G		G.		<b>*</b>				
REST brand driven by science, innovation, nature - and customers								

BEST brand driven by science, innovation, nature - and customers





### **BRAND STRATEGY**



CATEGORY

DRIVEN FOCUS








### **BRAND IDENTITY & GUIDELINE**



#### **SCIENCE IS IN OUR NATURE**

An outside in mindset of solutions & benefits, combined with science & nature



















Premium Exclusivity Confidence



CANNASEN\*



Relief & Balance Medical & Pharma Real & Scandinavian






















### **SALES STRATEGY**

Accelerating business growth with the right partners - Faster, Smarter







### **SALES STRATEGY**

CANNASEN®

Focused Pipeline

**ASIA** 

**AFRICA** 

**NORTH AMERICA** 

**SOUTH AMERICA** 

**EUROPE** 

**OCEANIA** 




Individual strategies &

Distribution plans



### **2023 FORECAST PROJECTION**








### **LONG TERM PIPELINE**

CANNASEN® SCIENCE IS IN OUR NATURE

A three-year forecast based on qualified leads





### **THE TEAM**





## A PASSIONATE, DIVERSE TEAM BELIEVES IN OUR PURPOSE

#### A MANAGEMENT TEAM MED COMPLEMENTARY SKILLS

Biochemistry & Medical Industry knowhow

Finance, Administration & Funding expertise

Growth, Transformation & Marketing expertise

Sales and Business
Development expertise



Lone Henriksen



Gitte Lund Henriksen
CFO/PARTNER



Heidi Ahlefeldt-Laurvig coo & cmo



Mikkel Nielsen
INTERNATIONAL SALES DIRECTOR





### WHY INVEST IN CS MEDICA



#### A DANISH-BASED MEDTECH GROWTH COMPANY

Harnessing medical cannabis and cannabinoid technology within pain relief and wellbeing.

#### A UNIQUE CBD TECHNOLOGY

To utilize on a broad range of segments and solutions.

#### READY TO CAPITALIZE FURTHER AND FASTER ON FIRST MOVER ADVANTAGES

With a specialized team, unique CBD technology & finished products we match a huge market potential and needs.









